Bristol Myers Squibb CFO David V. Elkins sold 25,519 shares in the open market on April 1, 2026, for about $1.57 million at $61.60 per share. Open-market sales by a chief financial officer tend to draw attention because the CFO is closely involved in financial reporting, capital allocation, and visibility into company performance and risks. This trade matters mainly as a signal of insider behavior: it represents a voluntary sale at a known price, rather than an automatic or company-arranged transaction. Investors often compare open-market selling to other insider filings to judge whether activity is routine. In this case, the only other noted recent insider actions were non-open-market acquisitions by other executives on March 10, 2026, at no cost, which are commonly tied to equity compensation (such as stock grants) rather than a deliberate purchase decision. Over the last 30 days, this is the only reported insider trade for CELG-RI, and it is a sale. With no additional recent buys or multiple sales from the same insider listed, the available data points to a single, notable transaction rather than a broader pattern of insider selling.